Abstract
Target discovery for cancer is undergoing a sort of revival with an increasing need for improved therapeutics. Likewise, the strategies to discover new and better therapeutic targets have come full circle, with greater emphasis placed upon targets that are functionally relevant to the disease process. In this article, we review the evolution of cancer target discovery and discuss random homozygous gene perturbation, an emerging technology that combines the practicality of screening for new targets by emphasizing function as the primary criterion, with cutting-edge advances in gene-based screening of all potential targets in a cell.
Original language | English |
---|---|
Pages (from-to) | 617-623 |
Number of pages | 7 |
Journal | Future Oncology |
Volume | 5 |
Issue number | 5 |
DOIs | |
State | Published - 2009 |
Keywords
- Cancer
- Drug resistance
- RHGP
- Random homozygus gene perturbation
- SiRNA
- Target discovery